

**UW PACC** Psychiatry and Addictions Case Conference UW Medicine | Psychiatry and Behavioral Sciences

# **ANTIPSYCHOTIC POLYPHARMACY**

### RYAN KIMMEL, MD MEDICAL DIRECTOR – HOSPITAL PSYCHIATRY UWMC

UW Medicine





# **GENERAL DISCLOSURES**

The University of Washington School of Medicine also gratefully acknowledges receipt of educational grant support for this activity from the Washington State Legislature through the Safety-Net Hospital Assessment, working to expand access to psychiatric services throughout Washington State.




### **SPEAKER DISCLOSURES**

 $\checkmark$  No conflicts of interest.




**HERE'S WHAT PSYCHIATRISTS KNEW IN 1976** 



(Seeman, Proc. Nat. Acad. Sci. USA, 1976)

### DOPAMINE





#### AND THEN CLOZAPINE CAME ALONG AND DIDN'T NEED TO BLOCK AS MUCH DOPAMINE (45% OCCUPANCY VS. 70% OCCUPANCY), BUT WORKED BETTER...

 Clozapine has high 5-HT2A antagonism and 5-HT1A agonism. It also has 5-HT2C, 5-HT6, 5-HT7, D4, D3, D1, M1, and H1 binding.

 Since we don't really know why clozapine works, every subsequent antipsychotic has included a smattering of clozapine's binding profile...and a smattering of its problems.



#### ATYPICALS HAVE A RANGE OF D2 BINDING AFFINITIES, TOO

• Drug	Daily Dose (mg) D2	2 (Ki)
<ul> <li>risperidone</li> </ul>	4	6
<ul> <li>paliperidone</li> </ul>	6	6
<ul> <li>asenapine</li> </ul>	10	7
<ul> <li>iloperidone</li> </ul>	12	22
<ul> <li>olanzapine</li> </ul>	20	40
<ul> <li>quetiapine</li> </ul>	600	245
draw a straigh	<b>600</b> d Ki is logarithmic, so you can't at line graph with the atypicals predict relative rate of D2 side effect	343 ts.

Ν




# **INSERTING ABILIFY**

• Drug	Daily Dose (mg)	D2 (Ki)
<ul> <li>aripiprazole</li> </ul>	20	1.6
<ul> <li>risperidone</li> </ul>	4	6
• paliperidone	6	6
<ul> <li>asenapine</li> </ul>	10	7
<ul> <li>iloperidone</li> </ul>	12	22
<ul> <li>olanzapine</li> </ul>	20	40
<ul> <li>quetiapine</li> </ul>	600	245
<ul> <li>clozapine</li> </ul>	600	343




### **VISUALIZING A PARTIAL AGONIST**

(THERE MAY A WIDE DIFFERENCE BETWEEN THE SIMPLICITY OF THIS SLIDE AND THE COMPLEXITY OF REAL LIFE BIOLOGY.)








Copyright 2017 University of Washington



# METABOLIC SIDE EFFECTS AND ANTI-HISTAMINE BINDING TRACK TOGETHER



©2017 University of Washington

Copyright 2017 University of Washington

# **MY PITCH FOR CLOZAPINE**

- Clozapine is the only medication that consistently shows efficacy in patients refractory to trials of other first-generation and second-generation antipsychotics.
- The agranulocytosis rate is 0.8%, mostly in the 1<sup>st</sup> year of treatment. More problematic is the weight gain, sedation, sialorrhea, seizures, and myocarditis.



#### ALL CAUSE MORTALITY OVER 11 YEARS IN PATIENTS WITH SCHIZOPHRENIA (N=76,881)

Α	Adjusted HR (95% CI)			
Clozapine Perphenazine Polypharmacy Olanzapine Thioridazine Risperidone Haloperidol Quetiapine Other	0.74 (0.60-0.91) 1.00 1.08 (0.92-1.26) 1.13 (0.93-1.36) 1.14 (0.93-1.38) 1.34 (1.12-1.62) 1.37 (1.10-1.72) 1.41 (1.09-1.82) 1.45 (1.24-1.69)			_
		0	1	2

Tihonen et al., "11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). " Lancet, 2009 Aug 22;374(9690):620-7.



# **ANTIPSYCHOTIC POLYPHARMACY**

- Despite a lack of evidence for efficacy, the incidence of antipsychotic polypharmacy is rising (Mojtabai and Olfson 2010).
- In the last 40 years, pharmaceutical companies have not been able to develop a medication (or combo-pill) that replicate's clozapine's efficacy.
   So...why are so many prescribers employing antipsychotic polypharmacy?



### WHY WE TRY ANTIPSYCHOTIC POLYPHARMACY

- Avoiding side effects to full doses of the first med
- Mistaken assumption that adding quetiapine does not increase the EPS rate
- Trying to create a "super-atypical"
- Get stuck in cross-taper when patient got better
- Challenges of clozapine monitoring or afraid of clozapine side effects
- Underestimate the impact of poor antipsychotic adherence
- Patients with developmental disorders or dementia



#### SIDE EFFECTS OF ANTIPSYCHOTIC POLYPHARMACY

- Antipsychotic polypharmacy is associated with a higher risk of diabetes and a higher rate of the broader metabolic syndrome (Citrome, Jaffe et al. 2004; Correll, Frederickson et al. 2007).
- Antipsychotic polypharmacy leads to higher rates of anticholinergic med use to treat EPS (Patton, J Psychopharmacol, 2003).



# Getting Stuck In A Cross Taper

*Immediate vs. Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-Analysis.* Takuechi et al., Schizophr Bull, 2017

- 9 studies involving 1416 patients
- "Gradual" = 1, 2, 3, or 4 weeks
- No difference in outcomes



For Patients on Antipsychotic Polypharmacy:

Every client deserves the opportunity to be tried on a lower risk regimen. A trial of a different regimen, with a clinical need to switch back, is not a failure. It documents that you tried. – Molly Finnerty, MD

